Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients.
We report 10 cases of intestinal microsporidiosis due to Enterocytozoon bieneusi in renal transplant (RT) recipients who were treated with fumagillin. All patients presented with afebrile subacute diarrhea (median of 2 weeks), associated with abdominal cramps (n = 5), and weight loss (n = 6), a mean of 68 months after RT. The diagnosis was made by the identification of microsporidial spores in stools with the use of appropriate staining and confirmed by a specific polymerase chain reaction assay for E. bieneusi in 7 patients. Median CD4 cell count was 292 cells/mm(3). All patients received a median of 14 days of oral fumagillin (20 mg tid), and four patients also discontinued or tapered their immunosuppressive regimen (mycophenolate mofetil in 3, and azathioprine in 2). Clinical symptoms resolved rapidly with the clearance of microsporidial spores from stools in all patients. A severe but reversible thrombocytopenia was observed in one patient during fumagillin therapy, and another patient presented with abdominal cramps. Trough levels of tacrolimus measured in seven patients dropped below 5 ng/mL in six of them after 7-14 days of fumagillin. Intestinal microsporidiosis can cause subacute diarrhea in RT recipients. Fumagillin is an effective treatment with an acceptable safety profile, but monitoring of tacrolimus levels is warranted.
Champion
L
L
Department of Renal Transplantation, Saint Louis Hospital and Paris-Diderot Paris 7 University, Paris, France. laure.champion@bch.aphp.fr
Durrbach
A
A
Lang
P
P
Delahousse
M
M
Chauvet
C
C
Sarfati
C
C
Glotz
D
D
Molina
J-M
JM
D000328:Adult; D000368:Aged; D003510:Cyclohexanes / Q000627:therapeutic use*; D021862:Enterocytozoon; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D016881:Microsporidiosis / Q000188:drug therapy*; D008875:Middle Aged; D012189:Retrospective Studies; D012717:Sesquiterpenes / Q000627:therapeutic use
D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D012717:Sesquiterpenes; C026211:fumagillin